Analysis of demographics and the impact of adjuvant radiotherapy on a nationwide cohort of patients with high-grade spinal meningiomas
- PMID: 38410135
- PMCID: PMC10896623
- DOI: 10.1093/noajnl/vdae018
Analysis of demographics and the impact of adjuvant radiotherapy on a nationwide cohort of patients with high-grade spinal meningiomas
Abstract
Background: Although typically benign, 5% of spinal meningiomas (SMs) present with higher-grade features (World Health Organization grades 2 and 3). High-grade SMs are poorly studied and the role of adjuvant radiotherapy in their management remains controversial. We hence aimed to study the demographic characteristics of this rare tumor and investigate the outcomes associated with the use of surgery with adjuvant therapy in contrast to surgery alone.
Methods: The National Cancer Database was queried for patients with SMs from 2004 to 2017. Basic statistics were used to identify differences between low- and high-grade tumors in terms of baseline characteristics. Surgery with and without adjuvant radiotherapy were compared after (1:1) propensity-score matching. Kaplan-Meier survival analysis was conducted to study overall survival. All analyses were performed on R.
Results: A total of 13 184 patients diagnosed with SMs were included, of whom only 5% (n = 669) had high-grade SMs. Patients with high-grade SMs presented at a younger median age (57 years [IQR: 44-68] versus 65 years [54-75]; P < .001) and were more commonly males (33% vs 20%; P < .001). After propensity-score matching, survival analysis revealed similar overall survival outcomes in patients with high-grade SM undergoing both surgery and radiotherapy as compared to those only receiving surgery (P = .19).
Conclusions: This study reveals major demographic differences between high- and low-grade SMs. There were no benefits associated with the use of adjuvant radiotherapy. However, due to confounding, overall survival outcomes between patients receiving surgery alone and those receiving surgery with adjuvant radiotherapy are not causally interpretable.
Keywords: adjuvant radiotherapy; high grade; overall survival; spinal meningiomas; surgery.
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Conflict of interest statement
None declared.
Figures



Similar articles
-
The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis.J Neurooncol. 2025 Feb;171(3):629-636. doi: 10.1007/s11060-024-04880-3. Epub 2024 Nov 11. J Neurooncol. 2025. PMID: 39527384 Free PMC article.
-
Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry.J Neurooncol. 2020 Sep;149(2):293-303. doi: 10.1007/s11060-020-03604-7. Epub 2020 Aug 28. J Neurooncol. 2020. PMID: 32860156
-
Determining the role of adjuvant radiotherapy in the management of meningioma: a Surveillance, Epidemiology, and End Results analysis.Neurosurg Focus. 2019 Jun 1;46(6):E3. doi: 10.3171/2019.3.FOCUS1971. Neurosurg Focus. 2019. PMID: 31153148
-
Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.J Neurooncol. 2021 Apr;152(2):205-216. doi: 10.1007/s11060-020-03674-7. Epub 2021 Feb 26. J Neurooncol. 2021. PMID: 33635510 Review.
-
Adjuvant Radiotherapy Did Not Reduce Recurrence of World Health Organization Grade I Meningiomas with Venous Sinus Involvement: A Propensity Score Adjusted Analysis and Literature Review.World Neurosurg. 2019 Oct;130:e1015-e1019. doi: 10.1016/j.wneu.2019.07.068. Epub 2019 Jul 12. World Neurosurg. 2019. PMID: 31306847 Review.
Cited by
-
The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis.J Neurooncol. 2025 Feb;171(3):629-636. doi: 10.1007/s11060-024-04880-3. Epub 2024 Nov 11. J Neurooncol. 2025. PMID: 39527384 Free PMC article.
References
-
- WHO Classification of Tumours Editorial Board. Central Nervous System Tumours: Who Classification of Tumours. WHO Classification of Tumours; 2022.
LinkOut - more resources
Full Text Sources